Evicenter
MarkdownMedical informationP&T meetings
Duravyu (vorolanib intravitreal insert)

Wet age-related macular degeneration

Also known as EYP-1901
Manufacturer
EyePoint
Launch
Not announced
Last updated
140 sources

Section 6 of 6

References

140 sources

  1. Abbey (2026) (opens in a new tab)
  2. Abbey and Ribeiro (2025) (opens in a new tab)
  3. Abu Al-Burak et al. (2026) (opens in a new tab)
  4. Al-Khersan et al. (2022) (opens in a new tab)
  5. Almony et al. (2021) (opens in a new tab)
  6. American Academy of Ophthalmology (2024) (opens in a new tab)
  7. Bakri et al. (2024) (opens in a new tab)
  8. Baljoon et al. (2026) (opens in a new tab)
  9. Brown et al. (2000) (opens in a new tab)
  10. Brown et al. (2016) (opens in a new tab)
  11. Brown et al. (2020) (opens in a new tab)
  12. Brown et al. (2021) (opens in a new tab)
  13. Brown et al. (2024) (opens in a new tab)
  14. Bryan et al. (2025) (opens in a new tab)
  15. Butt et al. (2017) (opens in a new tab)
  16. Chambers et al. (2025) (opens in a new tab)
  17. Chu et al. (2024) (opens in a new tab)
  18. Ciulla et al. (2020) (opens in a new tab)
  19. ClinicalTrials.gov NCT01674569 (opens in a new tab)
  20. ClinicalTrials.gov NCT01674569 results (opens in a new tab)
  21. ClinicalTrials.gov NCT02348359 (opens in a new tab)
  22. ClinicalTrials.gov NCT02348359 results (opens in a new tab)
  23. ClinicalTrials.gov NCT04747197 (opens in a new tab)
  24. ClinicalTrials.gov NCT05381948 (opens in a new tab)
  25. ClinicalTrials.gov NCT05381948 API record (opens in a new tab)
  26. ClinicalTrials.gov NCT05381948 results (opens in a new tab)
  27. ClinicalTrials.gov NCT06668064 (opens in a new tab)
  28. ClinicalTrials.gov NCT06683742 (opens in a new tab)
  29. CMS Medicare Part B Payment Limit File (2026) (opens in a new tab)
  30. CMS Medicare Part B Spending by Drug (2026) (opens in a new tab)
  31. Cohen et al. (2021) (opens in a new tab)
  32. Congdon et al. (2004) (opens in a new tab)
  33. Csaky et al. (2008) (opens in a new tab)
  34. Dang et al. (2024) (opens in a new tab)
  35. Daniel et al. (2014) (opens in a new tab)
  36. Delcourt et al. (2026) (opens in a new tab)
  37. Dhoot (2025) (opens in a new tab)
  38. Dickson and James (2023) (opens in a new tab)
  39. Dinah and Ribeiro (2025) (opens in a new tab)
  40. Duker (2026) (opens in a new tab)
  41. Eichenbaum et al. (2025) (opens in a new tab)
  42. EyePoint DSMC recommendation announcement (2026) (opens in a new tab)
  43. EyePoint Form 10-K (2026) (opens in a new tab)
  44. EyePoint Form 10-Q (2026) (opens in a new tab)
  45. EyePoint investor conferences and scientific meeting announcement (2026) (opens in a new tab)
  46. EyePoint investor presentation (2026) (opens in a new tab)
  47. EyePoint LUCIA topline results announcement (2026) (opens in a new tab)
  48. EyePoint LUCIA topline results presentation (2026) (opens in a new tab)
  49. EyePoint LUGANO expanded results presentation (2026) (opens in a new tab)
  50. EyePoint LUGANO topline results announcement (2026) (opens in a new tab)
  51. EyePoint LUGANO topline results presentation (2026) (opens in a new tab)
  52. EyePoint Pharmaceuticals DAVIO 2 enrollment completion announcement (2023) (opens in a new tab)
  53. EyePoint Pharmaceuticals DAVIO 2 protocol (2024) (opens in a new tab)
  54. EyePoint Pharmaceuticals DAVIO 2 topline results announcement (2023) (opens in a new tab)
  55. EyePoint Pharmaceuticals DAVIO 2 topline results presentation (2023) (opens in a new tab)
  56. EyePoint Pharmaceuticals DSMC recommendation announcement (2025) (opens in a new tab)
  57. EyePoint Pharmaceuticals Form 10-K (2025) (opens in a new tab)
  58. EyePoint Pharmaceuticals Investor Day presentation (2022) (opens in a new tab)
  59. EyePoint Pharmaceuticals investor presentation (2024) (opens in a new tab)
  60. EyePoint Pharmaceuticals LUCIA first patient dosed announcement (2024) (opens in a new tab)
  61. EyePoint Pharmaceuticals LUGANO enrollment completion announcement (2025) (opens in a new tab)
  62. EyePoint Pharmaceuticals LUGANO first patient dosed announcement (2024) (opens in a new tab)
  63. EyePoint Pharmaceuticals phase 3 enrollment completion announcement (2025) (opens in a new tab)
  64. EyePoint Pharmaceuticals R&D Day presentation (2024) (opens in a new tab)
  65. EyePoint second quarter 2026 results announcement (2026) (opens in a new tab)
  66. EyePoint strategic prioritization announcement (2026) (opens in a new tab)
  67. EyePoint third quarter 2026 results announcement (2026) (opens in a new tab)
  68. FDA Non-Inferiority Clinical Trials to Establish Effectiveness guidance (2016) (opens in a new tab)
  69. Flavin et al. (2024) (opens in a new tab)
  70. Fleckenstein et al. (2021) (opens in a new tab)
  71. Fonteh et al. (2022) (opens in a new tab)
  72. Franco et al. (2026) (opens in a new tab)
  73. Friedman et al. (2004) (opens in a new tab)
  74. GBD 2021 Global AMD Collaborators (2025) (opens in a new tab)
  75. Genentech LUCENTIS prescribing information (2024) (opens in a new tab)
  76. Genentech SUSVIMO prescribing information (2025) (opens in a new tab)
  77. Genentech VABYSMO prescribing information (2026) (opens in a new tab)
  78. Gohil et al. (2015) (opens in a new tab)
  79. Heier et al. (2022) (opens in a new tab)
  80. Holekamp et al. (2022) (opens in a new tab)
  81. Holz et al. (2015) (opens in a new tab)
  82. Holz et al. (2020) (opens in a new tab)
  83. Jackson et al. (2017) (opens in a new tab)
  84. Khurana et al. (2023) (opens in a new tab)
  85. Klein et al. (2007) (opens in a new tab)
  86. Kuznik et al. (2025) (opens in a new tab)
  87. Lanzetta et al. (2024) (opens in a new tab)
  88. Leandro et al. (2017) (opens in a new tab)
  89. Liu et al. (2024) (opens in a new tab)
  90. Loewenstein et al. (2024) (opens in a new tab)
  91. McGuire et al. (2026) (opens in a new tab)
  92. MedPAC (2026) (opens in a new tab)
  93. Monés et al. (2021) (opens in a new tab)
  94. National Eye Institute (2021) (opens in a new tab)
  95. Niazi et al. (2020) (opens in a new tab)
  96. NICE (2018) (opens in a new tab)
  97. Obeid et al. (2018) (opens in a new tab)
  98. Ocular Therapeutix first quarter 2026 results announcement (2026) (opens in a new tab)
  99. Ocular Therapeutix Form 10-Q (2026) (opens in a new tab)
  100. Ocular Therapeutix second quarter 2026 results announcement (2026) (opens in a new tab)
  101. Paneerselvam et al. (2026) (opens in a new tab)
  102. Patel (2018) (opens in a new tab)
  103. Patel and Ribeiro (2025) (opens in a new tab)
  104. Patel et al. (2024) (opens in a new tab)
  105. Pitsillidou et al. (2026) (opens in a new tab)
  106. Prenner et al. (2015) (opens in a new tab)
  107. Regeneron EYLEA HD prescribing information (2026) (opens in a new tab)
  108. Regeneron EYLEA prescribing information (2024) (opens in a new tab)
  109. Regillo (2024) (opens in a new tab)
  110. Rein et al. (2022) (opens in a new tab)
  111. Reitan et al. (2023) (opens in a new tab)
  112. Rosenfeld et al. (2006) (opens in a new tab)
  113. Rowe et al. (2025) (opens in a new tab)
  114. Rudnicka et al. (2015) (opens in a new tab)
  115. Sayed et al. (2024) (opens in a new tab)
  116. Schmidt et al. (2026) (opens in a new tab)
  117. Schmidt-Erfurth et al. (2014) (opens in a new tab)
  118. Shah (2026) (opens in a new tab)
  119. Sharma et al. (2000) (opens in a new tab)
  120. Sheth et al. (2024) (opens in a new tab)
  121. Siddiqui et al. (2022) (opens in a new tab)
  122. Siktberg et al. (2023) (opens in a new tab)
  123. Singh and Sørensen (2012) (opens in a new tab)
  124. Sivaprasad et al. (2025) (opens in a new tab)
  125. Sood et al. (2022) (opens in a new tab)
  126. Spaide et al. (2020) (opens in a new tab)
  127. Thomas et al. (2026) (opens in a new tab)
  128. Van Vu et al. (2024) (opens in a new tab)
  129. Varano et al. (2015) (opens in a new tab)
  130. Viola et al. (2024) (opens in a new tab)
  131. Vision Loss Expert Group of the Global Burden of Disease Study (2024) (opens in a new tab)
  132. Vu et al. (2021) (opens in a new tab)
  133. Vukicevic et al. (2016) (opens in a new tab)
  134. Windsor et al. (2018) (opens in a new tab)
  135. Wong et al. (2008) (opens in a new tab)
  136. Wong et al. (2014) (opens in a new tab)
  137. Wykoff (2024a) (opens in a new tab)
  138. Wykoff et al. (2024b) (opens in a new tab)
  139. Xu et al. (2026) (opens in a new tab)
  140. Zhang et al. (2023) (opens in a new tab)